Welcome
RAS oncogenes were considered undruggable for decades. Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021. Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.
The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges. At the same time, we plan to nurture dialogue between clinicians, preclinical as well as industrial researchers to envision how current research may guide future clinical practice.
We are inviting basic researchers, clinicians, and pharmaceutical scientists to join us in Salamanca, Spain, in September 2023, at our symposium Targeting RAS: new avenues and challenges.
Targeting RAS
Symposium
13th – 15th
September
2023
Welcome
Targeting RAS, new challenges and avenues. RAS oncogenes were considered undruggable for decades.
Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021.
Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.
The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges.
At the same time, we plan to nurture dialogue between clinicians, preclinical as well as clinical industrial researchers to envision how current research may guide future clinical practice.
Program
Short talk selected from abstracts | Patricia Santofimia Castaño, Centre de Recherche en Cancérologie de Marseille, INSERM, France “Targeting NUPR1-dependet Stress Granules Formation as an Efficient Strategy to Induce Synthetic Lethality In KrasG12D-Dependent Tumors”
Speakers
Channing J. Der
Chiara Ambrogio
Christina Kiel
Christopher Counter
Colin Lindsay
Dafna Bar-Sagi
Daniel Abankwa
David Tuveson
Ernest Nadal
Frank McCormick
Ian Prior
James Christensen
Julian Downward
Kairbaan Hodivala-Dilke
Kevan Shokat
Luis Paz-Ares
Mariano Barbacid
Mathew Holderfield
Owen Sansom
Pablo Rodríguez-Viciana
Pedro Beltran
Piero Crespo
Pilar Garrido
Rati Verma
René Bernards
Ruth Nussinov
Shiva Malek
Silve Vicent
Udai Banerji
Walter Kolch
Xosé R. Bustelo
Yibing Shan
Registration
Event Location
Palacio de Congresos Salamanca
Subscribe
to our Newsletter
For direct information about the symposium and to find out about the latest news.
Targeting RAS – New challenges and avenues has been made possible thanks to:
Any questions?
Ask us
If you need additional information or would like to know any specific details, please contact us.